Skip to main content

Market Overview

Tonix Plans Regulatory Filing To Kick Off Study Of Alcohol Use Disorder Drug

Share:
Tonix Plans Regulatory Filing To Kick Off Study Of Alcohol Use Disorder Drug

Shares of nano-cap biotech Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) were volatile Thursday morning following an announcement concerning its pre-investigational new drug application meeting with the U.S Food and Drug Administration.

Following the receipt of the minutes of the Type B, pre-IND meeting with the FDA, Tonix said the agency provided guidance and feedback supporting its clinical development plans for TNX-102 SL, a potential treatment for alcohol use disorder (AUD).

The company said it now plans to submit an IND application in the first quarter of 2020 that would support a Phase 2 proof-of-concept study.

See Also: Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio

Why It's Important For Tonix And AUD

About 36 million adults in the U.S. are estimated to have AUD, which is a chronic relapsing brain disease characterized by compulsive alcohol use, loss of control over alcohol intake and a negative emotional state when not using alcohol.

Tonix believes the rate of successful recovery after detox can be improved by improving sleep quality.

TNX-102 SL, the company's lead compound, is also being evaluated for post-traumatic stress disorder, or PTSD, fibromyalgia and agitation in Alzheimer's disease.

For PTSD, TNX-102 SL is in Phase 3 development. The company expects to report interim and top-line results from the study next year.

Tonix shares traded higher by nearly 10% in Thursday's pre-market session, but were down more than 9% to $1.32 at at time of publication.

 

Related Articles (TNXP)

View Comments and Join the Discussion!

Posted-In: alcohol use disorder TNX-102 SLNews Health Care FDA General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com